RELISTOR 20 MG — DIN 02308215
METHYLNALTREXONE BROMIDE : 20 MG · SALIX PHARMACEUTICALS INC · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is RELISTOR?
RELISTOR 20 MG contains METHYLNALTREXONE BROMIDE : 20 MG. It is listed in the Health Canada Drug Product Database under DIN 02308215, held by SALIX PHARMACEUTICALS INC, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 18-Jan-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is RELISTOR used for?
Treatment of opioid-induced constipation in patients with advanced illness, receiving palliative care, when response to laxatives has been insufficient. Used as an adjunct therapy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Methylnaltrexone Bromide cost around the world?
Methylnaltrexone Bromide is listed on 3 of the national price registers Nexara ingests. Each country publishes on a different basis, so figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Austria publishes a KVP (Kassenverkaufspreis); Czechia publishes a max producer price (ex-factory); Luxembourg publishes a reimbursement. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed |
|---|---|---|---|
| Austria | KVP (Kassenverkaufspreis) | 1 | 2 |
| Czechia | max producer price (ex-factory) | 1 | 2 |
| Luxembourg | reimbursement | 2 | 2 |
6 pack listings across 4 brand entries and 3 price bases, refreshed 05 Sep 2026. Ranges span every Methylnaltrexone Bromide pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Methylnaltrexone Bromide in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
Only one market authorization holder has a Canadian DIN containing Methylnaltrexone Bromide — 3 DINs, of which 1 are currently marketed. There is no second Canadian source today, so a supply interruption on this holder has no domestic substitute at the same molecule.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| SALIX PHARMACEUTICALS INC | 3 | 1 | RELISTOR | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 20 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | SUBCUTANEOUS |
| Pack configuration (monograph) | Vial (12 mg/0.6mL); Vial plus syringe with retractable needle; Pre-Filled Syringes (8 mg/0.4mL & 12 mg/0.6 mL). |
| Storage | Not explicitly detailed in provided text summary (Table of Contents lists page 25), but typically 15-30°C. (Note: Text provided ends before specific storage temp). |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Methylnaltrexone Bromide |
|---|---|
| ATC code | A06AH01 |
| AHFS class | 56:92.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02308215 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2308215 |
| Brand name | RELISTOR |
| Generic / active ingredient | METHYLNALTREXONE BROMIDE : 20 MG |
| Market authorization holder | SALIX PHARMACEUTICALS INC |
| Health Canada schedule | Prescription |
| ATC code | A06AH01 |
| ATC anatomical main group | A — Alimentary tract and metabolism |
| ATC therapeutic subgroup | A06AH |
| Current status | MARKETED |
| Status date | 18-Jan-2021 |
| Original market date | 2008-05-07 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Subcutaneous injection. Advanced illness: 8 mg (weight 38 to <62 kg) or 12 mg (62 to 114 kg). Patients outside these ranges should be dosed at 0.15 mg/kg. Administer as an adjunct therapy.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to any components; known or suspected mechanical gastrointestinal obstruction or acute surgical abdomen.
Warnings and precautions
Risk of GI perforation in patients with reduced structural integrity of the GI wall. Discontinue if severe/persistent diarrhea or worsening abdominal symptoms occur. Caution with GI lesions.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
1 of 3 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| RELISTOR | 20 MG | SOLUTION | SALIX PHARMACEUTICALS INC | APPROVED | 02356481 |
| RELISTOR | 20 MG | SOLUTION | SALIX PHARMACEUTICALS INC | APPROVED | 02356503 |
2 · Same class — other molecules in ATC A06AH
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Naloxegol | MOVANTIK | 2 | 2 | Yes |
| Methylnaltrexone Bromide | RELISTOR | 3 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC A06A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| A06AB | Bisacodyl · Bisacodyl, Combinations · Cascara · Cascara, Combinations · Castor Oil · +9 more | 239 | 25 |
| A06AA | Docusate Sodium · Docusate Sodium, Combinations · Liquid Paraffin · Liquid Paraffin, Combinations | 144 | 22 |
| A06AD | Lactulose · Macrogol · Macrogol, Combinations · Magnesium Oxide · Magnesium Sulphate · +5 more | 86 | 21 |
| A06AX | Glycerol · Linaclotide · Lubiprostone · Other Laxatives · Plecanatide · +2 more | 30 | 14 |
| A06AG | Bisacodyl · Combinations · Docusate Sodium, Incl Combinations · Sodium Phosphate | 7 | 1 |
| A06AC | Ispaghula (Psylla Seeds) · Ispaghula, Combinations · Linseed · Methylcellulose · Polycarbophil Calcium · +2 more | 79 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is RELISTOR called?
Also recorded in Canada as: 0.6 ML methylnaltrexone bromide 20 MG/ML Prefilled Syringe [Relistor] (US), 0.4 ML methylnaltrexone bromide 20 MG/ML Prefilled Syringe [Relistor] (US), methylnaltrexone bromide 150 MG Oral Tablet [Relistor] (US), 0.6 ML methylnaltrexone bromide 20 MG/ML Injection [Relistor] (US), 0.6 ML methylnaltrexone bromide 20 MG/ML Prefilled Syringe (US), 0.4 ML methylnaltrexone bromide 20 MG/ML Prefilled Syringe (US), methylnaltrexone bromide 150 MG Oral Tablet (US), 0.6 ML methylnaltrexone bromide 20 MG/ML Injection (US), METHYLNALTREXONE BROMIDE (US).
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.